Kim HJ, Lee S, Koo YJ, Kwon E, Kim HJ, Choi JY, Kim JS. Tacrolimus for Treating Orbital and Cranial Form of Idiopathic Inflammatory Pseudotumors.
J Clin Neurol 2020;
16:674-680. [PMID:
33029975 PMCID:
PMC7541994 DOI:
10.3988/jcn.2020.16.4.674]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Revised: 08/08/2020] [Accepted: 08/10/2020] [Indexed: 11/17/2022] Open
Abstract
Background and Purpose
Orbital and cranial form of idiopathic inflammatory pseudotumors (IIPs) are rare disorders with heterogeneous clinical presentations. Corticosteroids have been the first-line treatment for IIPs, but they are not always effective.
Methods
We reviewed the medical records of three patients with orbital or cranial form of IIP who were treated with tacrolimus as an adjuvant treatment.
Results
The three patients showed favorable outcomes with the addition of tacrolimus, which is a calcineurin inhibitor that inhibits T-cell activation and T-cell-dependent B-cell activation.
Conclusions
Tacrolimus may be a safe and effective immunosuppressant for refractory or relapsing form of orbital or cranial IIPs.
Collapse